National and Kapodistrian University of Athens
Μηχανισμοί ενεργοποίησης λευκοκυττάρων με ανοσοενισχυτικά πεπτίδια του θύμου αδένα: ανάπτυξη μεθόδου αξιολόγησης της δραστικότητας των πεπτιδίων
Abstract
dc:descriptionThe aim of this thesis was to investigate the effect of proTα(100-109) and intact prothymosin (proTα) on basic cell functions of innate immunity cells expressing TLR-4 and to develop/evaluate an immunoassay to quantify proTα(100-109) extracellularly, in order to elucidate its mode of action. The activation of neutrophils and monocytes with proTα(100-109) or proTα enhanced their basic functions (phagocytosis, oxidative burst and cytotoxicity) and restored their suppressed functions in breast cancer patients to the levels of healthy individuals. Furthermore, using polyclonal antibodies, we developed a competitive ELISA for proTα(100-109) and determined its concentration in vitro, in supernatants of cells led to cell death, in vivo in the serum of mice infected with bacteria and ex vivo in human sera. Specifically, the levels of proTα(100-109) were higher in apoptotic supernatants compared to low concentrations in the corresponding controls. BALB/c and C57BL/6 mice infected in vivo with five bacterial strains showed differences in the concentration of proTα(100-109) depending on the strain, breeding conditions and the type of pathogen. In general, the levels of proTα(100-109) before infection were low and gradually increased during the progress of infection. Using MALDI-TOF mass spectrometry, we detected a peak corresponding to the molecular mass of the decapeptide only in sera of infected animals. In an aggressive model of lethal sepsis in ICR mice, using Klebsiella pneumoniae that is endocytosed, we observed a gradual increase in the concentration of proTα(100-109), with maximal levels determined at 48 hours postinfection. In animals infected with a standard strain of Klebsiella, we observed variations and activation mainly of necrotic death pathways, as the bacterium was not endocytosed. Finally, we determined the levels of proTα(100-109) in sera of healthy individuals, pediatric patients and patients hospitalized in ICU. ProTα(100-109) levels in healthy subjects were very low, whereas in infected children, we detected higher concentrations of the decapeptide compared to children with autoinflammatory diseases, where the concentration of proTα(100-109) was low. ICU patients’ samples serially collected from admission to exit, showed variable proTα(100-109) concentrations during the hospitalization of patients who developed bacterial infections, which were correlated with clinical symptoms and laboratory markers. In contrast, the concentration of proTα(100-109) was minimal in ICU patients who did not develop an infection. The results of this thesis suggest that proTα(100-109) acts as an adjuvant on neutrophils and monocytes and, eventually could be used as an immunotherapeutic molecule to enhance immune system functions in cancer patients. Moreover, the same molecule could be used as a diagnostic marker for the differential diagnosis between septic and aseptic inflammation, providing that analysis of a larger number of samples from infected patients confirms our results.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Samara, Pinelopi
- Σαμαρά, Πηνελόπη
Subjects
dc:subject × 19Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44116